Business
Entera Bio Announces Open Market Purchases of Company Stock by Board Members
TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company’s Chairman, have made open market purchases of the Company’s ordinary shares. These transactions follow an earlier open market purchase by Entera Bio’s Chief Executive Officer, Miranda Toledano, in December 2025. The purchases were
About this update from Entera Bio Ltd.
[{"type":"image","alt":"Entera Bio","displaySize":"","headline":null,"caption":"Entera Bio","className":"","disableSlideshowImg":false,"size":{"original":{"width":237,"height":138,"url":"https://media.zenfs.com/en/globenewswire.com/a305198754d6a07fdaecab02b3a9d515"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PKeefwE624EAwJoXBY3bXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a305198754d6a07fdaecab02b3a9d515","width":237,"height":138}},"lazy":false},{"type":"text","content":"TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company’s Chairman, have made open market purchases of the Company’s ordinary shares. These transactions follow an earlier open market purchase by Entera Bio’s Chief Executive Officer, Miranda Toledano, in December 2025.","length":506,"tagName":"p"},{"type":"text","content":"The purchases were made by Geno J. Germano, Chairman of the Board; Steven D. Rubin, Director; Haya Taitel, Director; and Sean Ellis, Director. The shares were acquired in open market transactions at prevailing market prices. Details regarding the transactions, including the number of shares purchased and the purchase prices, are reported in filings with the U.S. Securities and Exchange Commission.","length":400,"tagName":"p"},{"type":"text","content":"All transactions were conducted in compliance with applicable securities laws and Entera Bio’s insider trading policies.","length":120,"tagName":"p"},{"type":"text","content":"About Entera BioEntera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo-...